Fig. 4.

Scl_N93AFc antagonizes Scl inhibition of the Wnt pathway, promotes bone formation, and increases femoral bone mass and length. Eight-week-old female C57BL/6 mice treated with purified Scl_N93AFc (0.5 mg/kg) for 2 weeks by bi-weekly subcutaneous injections. a Three-dimensional reconstructions of distal femurs from X-ray computed µCT scans. b–e Femoral µCT analysis of trabecular bone architecture in terms of b bone volume as a percentage of total trabecular volume (BV/TV) and c–e trabecular number (Tb.N), thickness (Tb.Th), and separation (Tb.Sp). f Femoral length measurement. Group size, n = 7 per vehicle group, n = 8 per Scl_N93AFc group. g–i Dynamic histomorphometry analysis of tibial bone formation parameters: mineralizing surface to bone surface ratio (MS/BS), mineral apposition rate (MAR), and bone formation rate (BFR). Group size, n = 6 per vehicle group, n = 5 per Scl_N93AFc group, randomly selected. j Quantitative analysis of osteoclast surface per bone surface (Oc.S/BS). Group size, n = 5 per vehicle group, n = 6 per Scl_N93AFc group, randomly selected. Significance was assessed using unpaired, two-tailed Student's t test